pharmacy scholarship: zac cox

parker r, henslee a, cox zl. a clinical conundrum: the pharmacist's role in evaluating comorbid urinary incontinence and heart failure. sr care pharm. 2021;36(3):142-146. doi:10.4140/tcp.n.2021.142

ivey-miranda jb, wetterling f, gaul r, sheridan s, asher jl, rao vs, maulion c, mahoney d, mebazaa a, gray ap, burkhoff d, cowie mr, cox zl, butler j, fudim m, mcdonald k, damman k, borlaug ba, testani jm. changes in inferior vena cava area represent a more sensitive metric than change in filling pressures during experimental manipulation of intravascular volume and tone. eur j heart fail. 2021;doi:10.1002/ejhf.2395

cox zl, rao vs, ivey-miranda jb, moreno-villagomez j, mahoney d, ponikowski p, biegus j, turner jm, maulion c, bellumkonda l, asher jl, parise h, wilson pf, ellison dh, wilcox cs, testani jm. compensatory post-diuretic renal sodium reabsorption is not a dominant mechanism of diuretic resistance in acute heart failure. eur heart j. 2021;doi:10.1093/eurheartj/ehab620

cox zl, collins sp, aaron m, hernandez ga, iii atm, davidson bt, fowler m, lindsell cj, harrell fe jr, jenkins ca, kampe c, miller kf, stubblefield wb, lindenfeld j. efficacy and safety of dapagliflozin in acute heart failure: rationale and design of the dictate-ahf trial. am heart j. 2021;232:116-124. doi:10.1016/j.ahj.2020.10.071

ivey-miranda jb, stewart b, cox zl, mccallum w, maulion c, gleason o, meegan g, amatruda jg, moreno-villagomez j, mahoney d, turner jm, wilson fp, estrella mm, shlipak mg, rao vs, testani jm. fgf-23 (fibroblast growth factor-23) and cardiorenal interactions. circ heart fail. 2021:circheartfailure121008385. doi:10.1161/circheartfailure.121.008385

turner jm, cox zl, testani jm. improving renal function during diuresis: useful information or just noise? eur j heart fail. 2021;23(7):1131-1133. doi:10.1002/ejhf.2267

rao vn, murray e, butler j, cooper lb, cox zl, fiuzat m, green jb, lindenfeld j, mcguire dk, nassif me, o'brien c, pagidipati n, sharma k, vaduganathan m, vardeny o, fonarow gc, mentz rj, greene sj. in-hospital initiation of sodium-glucose cotransporter-2 inhibitors for heart failure with reduced ejection fraction. j am coll cardiol. 2021;78(20):2004-2012. doi:10.1016/j.jacc.2021.08.064

cox zl, sarrell ba, cella mk, tucker b, arroyo jp, umanath k, tidwell w, guide a, testani jm, lewis jb, dwyer jp. multinephron segment diuretic therapy to overcome diuretic resistance in acute heart failure: a single-center experience. j card fail. 2021;doi:10.1016/j.cardfail.2021.07.016

rao vs, ivey-miranda jb, cox zl, riello r, griffin m, fleming j, soucier r, sangkachand p, o'brien m, lorusso f, d'ambrosi j, churchwell k, mahoney d, bellumkonda l, asher jl, maulion c, turner jm, wilson fp, collins sp, testani jm. natriuretic equation to predict loop diuretic response in patients with heart failure. j am coll cardiol. 2021;77(6):695-708. doi:10.1016/j.jacc.2020.12.022

li dl, cox zl, richardson td, kanagasundram an, saavedra pj, shen st, montgomery ja, murray kt, roden dm, stevenson wg. quinidine in the management of recurrent ventricular arrhythmias: a reappraisal. jacc clin electrophysiol. 2021;7(10):1254-1263. doi:10.1016/j.jacep.2021.03.024

rao vs, maulion c, asher jl, ivey-miranda jb, cox zl, moreno-villagomez j, mahoney d, turner jm, wilson fp, wilcox cs, testani jm. renal negative pressure treatment as a novel therapy for heart failure-induced renal dysfunction. am j physiol regul integr comp physiol. 2021;321(4):r588-r594. doi:10.1152/ajpregu.00115.2021

burns h, russell l, cox zl. statin-induced rhabdomyolysis from azithromycin interaction in a patient with heterozygous slco1b1 polymorphism. j clin pharm ther. 2021;46(3):853-855. doi:10.1111/jcpt.13327

cox zl, lai p, lewis cm, lindenfeld j. body mass index and all-cause readmissions following acute heart failure hospitalization. int j obes (lond). 2020;44(6):1227-1235. doi:10.1038/s41366-019-0518-6

cox zl, lai p, lewis cm, lindenfeld j. change in admission blood glucose from chronic glycemic status in acute heart failure hospitalization and 30-day outcomes: a retrospective analysis. int j cardiol. 2020;299:180-185. doi:10.1016/j.ijcard.2019.07.069

cox zl, lai p, lindenfeld j. decreases in acute heart failure hospitalizations during covid-19. eur j heart fail. 2020;22(6):1045-1046. doi:10.1002/ejhf.1921

cox zl, hung r, lenihan dj, testani jm. diuretic strategies for loop diuretic resistance in acute heart failure: the 3t trial. jacc heart fail. 2020;8(3):157-168. doi:10.1016/j.jchf.2019.09.012

felker gm, ellison dh, mullens w, cox zl, testani jm. diuretic therapy for patients with heart failure: jacc state-of-the-art review. j am coll cardiol. 2020;75(10):1178-1195. doi:10.1016/j.jacc.2019.12.059

cox zl, sury k, rao vs, ivey-miranda jb, griffin m, mahoney d, gomez n, fleming jh, inker la, coca sg, turner j, wilson fp, testani jm. effect of loop diuretics on the fractional excretion of urea in decompensated heart failure. j card fail. 2020;doi:10.1016/j.cardfail.2020.01.019

griffin m, rao vs, ivey-miranda j, fleming, j, mahoney d, maulion c, suda n, siwakoti k, ahmad t, jacoby d, riello r, bellumkonda l, cox z, collins s, jeon s, turner jm, wilson fp, butler j, inzucchi se, testani jm. empagliflozin in heart failure: diuretic and cardiorenal effects. circulation. 2020;142(11):1028-1039. doi:10.1161/circulationaha.120.045691

cox zl, testani jm. loop diuretic resistance complicating acute heart failure. heart fail rev. 2020;25(1):133-145. doi:10.1007/s10741-019-09851-9

cox zl, fleming j, ivey-miranda j, griffin m, mahoney d, jackson k, hodson dz, thomas d jr, gomez n, rao vs, testani jm. mechanisms of diuretic resistance study: design and rationale. esc heart fail. 2020;doi:10.1002/ehf2.12949

gorodeski ez, goyal p, cox zl, thibodeau jt, reay re, rasmusson k, rogers jg, starling rc. virtual visits for care of patients with heart failure in the era of covid-19: a statement from the heart failure society of america. j card fail. 2020;26(6):448-456. doi:10.1016/j.cardfail.2020.04.008

cox zl, stevenson lw. the weight of evidence for diuretics and parachutes. j am coll cardiol. 2020;76(6):680-683. doi:10.1016/j.jacc.2020.06.044

xiong l, chinaeke ee, lu k, lenihan dj, merritt te, cox zl. evaluation of severe myalgia induced by continuous-infusion bumetanide in patients with acute heart failure. pharmacotherapy. 2019.

sabato la, johnson dc, haglund n, keebler m, cox zl. pharmacokinetics of sildenafil in patients with a left ventricular assist device: a word of caution. asaio j. 2019;65(5):530-532. doi:10.1097/mat.0000000000000886

charokopos a, griffin m, rao vs, inker, l, sury k, asher j, turner j, mahoney d, cox zl, wilson fp, testani j. m. serum and urine albumin and response to loop diuretics in heart failure. clin j am soc nephrol. 2019;14(5):712-718.

cox zl, lai p, lewis cm, lindenfeld j, collins sp, lenihan dj. customizing national models for a medical center's population to rapidly identify patients at high risk of 30-day all-cause hospital readmission following a heart failure hospitalization. heart lung. 2018;47(4):290-296.

cox zl, lai p, lewis cm, lenihan dj. centers for medicare and medicaid services' readmission reports inaccurately describe an institution's decompensated heart failure admissions. clin cardiol. 2017;40(9):620-625.

tunney rk, jr., johnson dc, wang l, cox zl. impact of pharmacist intervention to increase compliance with guideline-directed statin therapy during an acute coronary syndrome hospitalization. ann pharmacother. 2017;51(5):394-400.

sabato la, mendes la, cox zl. restrictive cardiomyopathy associated with long-term use of hydroxychloroquine for systemic lupus erythematosus. j pharm pract. 2017;30(5):571-575.

cox zl, lewis cm, lai p, lenihan dj. validation of an automated electronic algorithm and "dashboard" to identify and characterize decompensated heart failure admissions across a medical center. am heart j. 2017;183:40-48.

haglund na, burdorf a, jones t, shostrom v, um j, ryan t, shillcutt s, fischer p, cox zl, raichlin e, anderson dr, lowes bd, dumitru i. inhaled milrinone after left ventricular assist device implantation. j card fail. 2015;21(10):792-797.

haglund na, cox zl, lee jt, song y, keebler me, disalvo tg, maltais s, lenihan dj, wigger ma. are peripherally inserted central catheters associated with increased risk of adverse events in status 1b patients awaiting transplantation on continuous intravenous milrinone? j card fail. 2014;20(9):630-637. doi: 10.1016/j.cardfail.2014.06.004

powers js, cox zl, young j, howell m, disalvo t. critical pathways: implementation of the coleman care transitions program in individuals hospitalized with congestive heart failure. j am geriatr soc. 2014;62(12):2442-2444. 10.1111/jgs.13174

cox zl, lenihan dj. loop diuretic resistance in heart failure: resistance etiology-based strategies to restoring diuretic efficacy. j card fail. 2014;20(8):611-622.

cox zl, mccoy ab, matheny me, bhave g, peterson nb, siew ed, lewis j, danciu i, bian a, shintani a, ikizler ta, neal eb, peterson jf. adverse drug events during aki and its recovery. clin j am soc nephrol. 2013;8(7):1070-1078.

cox zl, calcutt mw, morrison tb, akers ws, davis mb, lenihan dj. elevation of plasma milrinone concentrations in stage d heart failure associated with renal dysfunction. j cardiovasc pharmacol ther. 2013;18(5):433-438. doi: 10.1177/1074248413489773

mccoy ab, cox zl, neal eb, waitman lr, peterson nb, bhave g, siew ed, danciu i, lewis jb, peterson jf. real-time pharmacy surveillance and clinical decision support to reduce adverse drug events in acute kidney injury: a randomized, controlled trial. appl clin inform. 2012;3(2):221-238.

cox zl, nelsen cl, waitman lr, mccoy ja, peterson jf. effects of clinical decision support on initial dosing and monitoring of tobramycin and amikacin. am j health syst pharm. 2011;68(7):624-632.

wilson ns, hudson jq, cox zl, king t, finch ck. hyperkalemia-induced paralysis. pharmacotherapy. 2009;29(10):1270-1272. 10.1592/phco.29.10.1270